PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1360533-0	1992	PAF formation by human gastrointestinal mucosa/submucosa in-vitro: release by ricinoleic acid, and inhibition by 5-aminosalicylic acid.	Mesalamine	113-134	PCNA clamp associated factor	Homo sapiens	0-3	
1360533-2	1992	5-Aminosalicylic acid (25-100 micrograms mL-1) inhibited PAF release by ricinoleic acid in a concentration-dependent manner, and 50 micrograms mL-1 reduced the effect of A23187.	Mesalamine	0-21	PCNA clamp associated factor	Homo sapiens	57-60	
1359744-5	1992	The enhanced stimulation of PAF induced by A23187 was dose-dependently inhibited by sulphasalazine, 5-aminosalicylic acid and prednisolone, but not by sulfapyridine.	Mesalamine	100-121	PCNA clamp associated factor	Homo sapiens	28-31	
1794301-0	1991	Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid.	Mesalamine	90-111	PCNA clamp associated factor	Homo sapiens	11-37	
1794301-0	1991	Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid.	Mesalamine	90-111	PCNA clamp associated factor	Homo sapiens	39-42	
1794301-4	1991	5-ASA 25-100 micrograms/ml caused a 5-100% inhibition of the PAF release by 50 micrograms/ml ricinoleic acid.	Mesalamine	0-5	PCNA clamp associated factor	Homo sapiens	61-64	
1794301-5	1991	The authors conclude that PAF can be released by damage to human colonic mucosa/submucosa, and that the inhibition of PAF release in ulcerative colitis may at least partly explain the therapeutic effect of 5-ASA.	Mesalamine	206-211	PCNA clamp associated factor	Homo sapiens	26-29	
1794301-5	1991	The authors conclude that PAF can be released by damage to human colonic mucosa/submucosa, and that the inhibition of PAF release in ulcerative colitis may at least partly explain the therapeutic effect of 5-ASA.	Mesalamine	206-211	PCNA clamp associated factor	Homo sapiens	118-121